ACCESS Newswire
09 May 2022, 19:07 GMT+10
WESTPORT, CT / ACCESSWIRE / May 9, 2022 / CYduct Diagnostics, Inc. (OTC PINK:CYDX) ('CYduct') is pleased to announce it has joined BioCT, Connecticut's Biosciences Community.
Commenting on CYduct's membership into BioCT, Dominick Gatto, CYduct's Chief Executive Officer stated, 'We look forward to utilizing the many resources available thru BioCT's network and its many members.'
Mr. Gatto continued, 'I am pleased to continue our growth and development within the biosciences community of our home state, Connecticut. It has been our goal to build CYduct from and within Connecticut, utilizing primarily Connecticut resources when possible.' Our company is at the stage where innovative and strategic planning will assist in moving the company successfully forward, and the assistance found within the BioCT community will help us meet those plans and achieve our goals.'
About BioCT:
BioCT is the bioscience industry voice for Connecticut, dedicated to growing a vibrant ecosystem by supporting innovation, collaboration, networking, education, talent engagement and advocacy. BioCT brings together companies, institutions, entrepreneurs, investors, government, service providers, and other passionate, dedicated people, to build a thriving bioscience community to improve patients' lives and public health, while driving economic growth. Additional information is available on BioCT's website at: www.bioct.org.
About CYduct Diagnostics, Inc.:
CYduct Diagnostics Inc. is a medical device company pursuing innovations within the women's healthcare market, primarily breast healthcare and wellness. CYduct is focused on breast health and wellness through new testing methods that prioritize clinical integrity and patient privacy and convenience. The Company's history is rooted in providing quality medical products to healthcare markets across the United States. For more than 30 years, from medical schools to hospitals, physicians have relied on the Company to develop medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its line of products will be available on the Company's website at: www.CYductdx.com.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding the potential future plans and objectives of the Company, are forward-looking statements that involve significant risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. The inability to raise additional capital, and technical complications in research, product development and validation, among other things, could prevent the implementation of strategically significant plan(s) outlined above. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The Company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
CYduct Diagnostics, Inc.
Investor Relations +1-888-545-9112
SOURCE: CYduct Diagnostics, Inc.
Get a daily dose of Cleveland Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Cleveland Star.
More InformationSANTA CLARA, California: Executives at Nvidia have quietly been cashing in on the AI frenzy. According to a report by the Financial...
NEW YORK, New York - Global stock indices closed with divergent performances on Tuesday, as investors weighed corporate earnings, central...
TORONTO, Canada: Canadian Prime Minister Mark Carney announced late on June 29 that trade negotiations with the U.S. have recommenced...
Vancouver, Canada: A high-stakes legal showdown is brewing in the world of athleisure. Lululemon, the Canadian brand known for its...
LONDON, U.K.: British oil giant Shell has denied reports that it is in talks to acquire rival oil company BP. The Wall Street Journal...
NEW YORK, New York - U.S. stock markets closed firmly in positive territory to start the week Monday, with the S&P 500 and Dow Jones...
ABU DHABI, 19th June, 2025 (WAM) -- Cleveland Clinic Abu Dhabi has become the first and only research hospital in the UAE to receive...
ABU DHABI, 17th June, 2025 (WAM) -- Cleveland Clinic Abu Dhabi, part of the M42 group, has successfully introduced continuous infusion...
ABU DHABI, 9th June, 2025 (WAM) -- Cleveland Clinic Abu Dhabi has successfully performed the UAE's first robotic cytoreductive surgery...
ABU DHABI,16th May, 2025 (WAM) - Oracle Health, Cleveland Clinic, and G42 today announced a strategic partnership to develop a groundbreaking...
ABU DHABI, 6th May, 2025 (WAM) -- PureHealth and its subsidiary SEHA have partnered with the number one US children's hospital, Cincinnati...
Argentinian composer Lalo Schifrin, the genre-blending film and television composer behind the Mission: Impossible, Bullitt, and Cool...